ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

Biotechnology

Healthcare
$7.65 -0.75%

-$0.07 today

Market cap
$795.08M
Beta
1.06
P/E (TTM)
-6.7
EPS (TTM)
-$1.28
52W Low $7.23High $14.93

Volume 1.39M

Average 1.91M

ORIC Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

ORIC Pharmaceuticals, Inc.NASDAQ: ORIC

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $8.18M rose 1.3% year over year, behind the +12.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 5.9% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 11 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +15.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.18M-5.9% QoQ
Last fiscal yearDec 2025
$33.19M+15.1% YoY
LTMMar 2026
$33.29M+12.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.3%-100.0%-101.3 pp
1 year+15.1%-100.0%-115.1 pp
3-year CAGR+9.8%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
33.19M USD
Year-over-year change
+15.1%
4-year CAGR
+10.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ORIC compares with its peers on the latest reported figures

  • ORIC's LTM Mar 2026 selling, general & admin of $33.29M is the 7th highest of the 11 companies compared; the peer median is $37.28M.
  • Its year-over-year change of +12.6% is the 9th highest of 11, against a peer median of +29.7%.
  • Over three fiscal years its annual growth of +9.8% compares with a peer median of +35.7%.
ORIC Competitors Peer median
Selling, General & Admin for ORIC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$176.24M +26.9%+75.5%81.2%
NUVBNuvation Bio Inc.LTM Jun 2026$158.59M +32.6%+68.1%93.3%
VSTMVerastem, Inc.LTM Mar 2026$88.42M +83.1%+48.1%178.3%
JANXJanux Therapeutics, Inc.LTM Mar 2026$42.56M -1.1%+23.3%196.9%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M -27.9%-12.7%24.3%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$36.41M +35.2%+63.3%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$33.29M +12.6%+9.8%—
TYRATyra Biosciences, Inc.LTM Mar 2026$31.48M +21.6%+23.3%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$27.19M +59.1%+55.2%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$10.49M +24.0%+4.5%—
NVCTNuvectis Pharma, Inc.LTM Mar 2026$9.69M +36.8%+16.2%—
Peer median (excluding ORIC) $37.28M+29.7%+35.7%93.3%

Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.03M1.11M1.22M
Gross Profit00(1.03M)(1.11M)(1.22M)
Gross Margin—————
Research & Development56.86M61.68M85.17M114.07M109.82M
Selling, General & Admin22.01M25.09M25.61M28.82M33.19M
Operating Expenses78.87M91.77M109.75M141.79M141.78M
Depreciation & Amortization897K966K1.03M1.11M1.22M
EBITDA(77.82M)(85.8M)(99.67M)(126.74M)(128.25M)
EBITDA Margin—————
Operating Income(78.87M)(91.77M)(110.78M)(142.9M)(143M)
Operating Margin—————
Interest Income141K2.65M10.08M00
Interest Expense02.65M000
Other Income / Expenses156K2.65M10.08M15.05M13.54M
Income Before Tax(78.72M)(89.12M)(100.7M)(127.85M)(129.47M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(78.72M)(89.12M)(100.7M)(127.85M)(129.47M)
Net Margin—————
EPS (Basic)(2.07)(2.25)(1.96)(1.83)(1.47)
EPS (Diluted)(2.07)(2.25)(1.96)(1.83)(1.47)
Weighted Avg Shares37.95M39.66M51.45M69.73M87.79M
Weighted Avg Shares (Diluted)37.95M39.66M51.45M69.73M87.79M

ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

Intrinsic Alpha fair value

Locked

Current Price

$7.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.